Mineralys Therapeutics Statistics
Share Statistics
Mineralys Therapeutics has 49.77M shares outstanding. The number of shares has increased by 20.97% in one year.
| Shares Outstanding | 49.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.55M |
| Failed to Deliver (FTD) Shares | 242 |
| FTD / Avg. Volume | 0.14% |
Short Selling Information
The latest short interest is 1.39M, so 2.79% of the outstanding shares have been sold short.
| Short Interest | 1.39M |
| Short % of Shares Out | 2.79% |
| Short % of Float | 5.91% |
| Short Ratio (days to cover) | 10.39 |
Valuation Ratios
The PE ratio is -4.33 and the forward PE ratio is -3.86.
| PE Ratio | -4.33 |
| Forward PE | -3.86 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.29 |
| P/FCF Ratio | -3.83 |
| PEG Ratio | n/a |
Enterprise Valuation
Mineralys Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 23.76, with a Debt / Equity ratio of 0.
| Current Ratio | 23.76 |
| Quick Ratio | 23.76 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.3% and return on capital (ROIC) is -35.1%.
| Return on Equity (ROE) | -0.3% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -35.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.57M |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 46.77% in the last 52 weeks. The beta is 2.46, so Mineralys Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.46 |
| 52-Week Price Change | 46.77% |
| 50-Day Moving Average | 13.28 |
| 200-Day Moving Average | 12.7 |
| Relative Strength Index (RSI) | 44.02 |
| Average Volume (20 Days) | 174.91K |
Income Statement
In the last 12 months, Mineralys Therapeutics had revenue of $0 and earned -$71.90M in profits. Earnings per share was $-1.99.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -84.66M |
| Net Income | -71.90M |
| EBITDA | -84.66M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.99 |
Balance Sheet
The company has $49.30M in cash and $0 in debt, giving a net cash position of $49.30M.
| Cash & Cash Equivalents | 49.30M |
| Total Debt | 0 |
| Net Cash | 49.30M |
| Retained Earnings | -124.71M |
| Total Assets | 268.25M |
| Working Capital | 236.41M |
Cash Flow
In the last 12 months, operating cash flow was -$81.17M and capital expenditures $0, giving a free cash flow of -$81.17M.
| Operating Cash Flow | -81.17M |
| Capital Expenditures | 0 |
| Free Cash Flow | -81.17M |
| FCF Per Share | -2.24 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.82% |
| FCF Yield | -13.79% |
Analyst Forecast
The average price target for MLYS is $30, which is 153.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 153.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 9.27 |
| Piotroski F-Score | 1 |